Partnering opportunity

Molecular diagnostics of familial hyperaldosteronism type II

Summary

A German university developed a new molecular diagnostics of hyperaldosteronism. It facilitates better timely and adequate treatment of affected persons with high blood pressure due to familial hyperaldosteronism type II. The university is offering a license agreement to diagnostic companies.

Partner sought

The university is offering a license agreement to companies that are active in the field of genetic or molecular diagnostics, interested in applying the new technology, which is ready to use.

Description

More than a billion people worldwide suffer from high blood pressure, which is largely caused by lifestyle habits such as lack of physical exercise, obesity, diet, salt intake and alcohol consumption. Besides that genetic factors play an important role in hypertension. Hyperaldosteronism is supposed to be the most common reason for secondary hypertension accounting for 5 to 12 percent of patients with high blood pressure. The current diagnostic methods for the detection of familial hyperaldosteronism often result in a belated diagnosis. Researchers of a German university have identified mutations in the chloride channel encoding gene CNCL2 as a new hypertension disease gene. Pedigrees of eight kindreds were analyzed by Sanger sequencing and mutations were identified as indicated in the figure. The molecular diagnosis of CLCN2 facilitates better timely and adequate treatment of affected persons with hyperaldosteronism, especially of patients suffering from hyperaldosteronism in childhood and adolescence, and furthermore applies to disease risk assessment. In addition, this technology may give rise to novel therapy options for hyperaldosteronism targeting the mutated chloride channel ClC-2. This very specific genetic analysis does not need a further development and is ready to be used. The university offers a license agreement to companies specialized in molecular or genetic diagnostics, who will use the technology in their processes.

Advantages and innovations

The current diagnostic methods for the detection of familial hyperaldosteronism often result in a belated diagnosis. The heart circulatory system is already damaged. This invention represents a first diagnostic option for patients with familial hyperaldosteronism type II. It allows an early diagnosis and shows the probability to develop hyperaldosteronism if parents have an inherited defect (similar to estimation of familial cancer risk). It provides a timely and adequate treatment and risk assessment in reproductive medicine.

Development stage

Available for demonstration

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company